AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq by $4 billion.
Earnings season is now well under way, with a number of major companies due to release results in the coming week. Investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback